US Patent

US9216178 — Dry blend formulation of tetrahydrobiopterin

Formulation · Assigned to Biomarin Pharmaceutical Inc · Expires 2032-11-01 · 6y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent discloses dry blend powder formulations containing tetrahydrobiopterin and methods of making and using them.

USPTO Abstract

Dry blend powder formulations comprising a pharmaceutical formulation containing tetrahydrobiopterin, and methods of making and using the same, are disclosed herein.

Drugs covered by this patent

sapropterin-dihydrochloride (SAPROPTERIN DIHYDROCHLORIDE)

Patent Metadata

Patent number: US9216178
Jurisdiction: US
Classification: Formulation
Expires: 2032-11-01
Drug substance claim: No
Drug product claim: Yes
Assignee: Biomarin Pharmaceutical Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.